Aberrant regulation of cholesterol and lipid homeostasis leads to metabolic syndrome and cardiovascular diseases. microRNAs (miRNA) are short non-coding RNAs that control gene expression predominantly through post-transcriptional repression. They are implicated in the control of multiple physiological and pathological processes. However the specific roles of miRNAs in regulating cholesterol and lipoprotein metabolism are just beginning to be explored. Our previous work has shown that hsa-miR- 33a/b and its mouse homologue mmu-miR-33 (herein after referred to as miR-33), intronic miRNAs located within the sterol-regulatory element-binding protein (SREBP) 2 and 1 genes, respectively, in humans;regulate cholesterol homeostasis in concert with the SREBP host gene. MiR-33 inhibits the expression of the ATP-binding cassette (ABC) transporter, ABCA1, thereby attenuating cholesterol efflux to apoA1 and high-density lipoprotein (HDL) biogenesis. Conversely, silencing of miR-33 in vivo increased hepatic ABCA1 and plasma HDL. In addition, our recent preliminary data suggest that miR-33 also coordinates genes regulating fatty acid metabolism and insulin signaling. For example, miR-33 targets carnitine O- octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA- dehydrogenase (HADHB), key enzymes involved in the regulation of fatty acid oxidation, and insulin receptor substrate 2 (IRS2), which regulates insulin signaling. Thus, we hypothesize that inhibition of miR-33 may represent a therapeutic target for ameliorating cardiometabolic disease, including atherosclerosis and metabolic syndrome. The objective of this proposal is to determine the molecular mechanism underlying the miR-33-mediated responses in cardiometabolic disease. We propose the following specific Aims:
Aim 1. To delineate the role of miR-33 in regulating cholesterol metabolism, - oxidation of fatty acid and insulin signaling in vivo and Aim 2. To define the role of miR-33 in lipid metabolism, insulin signaling, and atherosclerosis in vivo.

Public Health Relevance

Aberrant regulation of cholesterol and lipid homeostasis leads to metabolic syndrome and cardiovascular diseases. Our recent data suggest that microRNA (miRNA) is important regulators in the control of lipoprotein metabolism and insulin signaling. MiR-33 inhibits the expression of the ATP-binding cassette (ABC) transporter, ABCA1, thereby attenuating cholesterol efflux to apoA1 and high-density lipoprotein (HDL) biogenesis. The proposal main goal is to investigate the mechanism by which miR-33 regulates lipid metabolism and cardiovascular related disorders. This work will provide critical insight into fundamental regulatory mechanism and may identify potential therapeutic strategies for the regulation of lipoprotein metabolism and insulin signaling, two hallmarks of the metabolic syndrome. ]

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL107953-02
Application #
8252159
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Hasan, Ahmed AK
Project Start
2011-04-06
Project End
2015-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
2
Fiscal Year
2012
Total Cost
$422,500
Indirect Cost
$172,500
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Goedeke, Leigh; Wagschal, Alexandre; Fernández-Hernando, Carlos et al. (2016) miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta 1861:2047-2052
Baldán, Ángel; Fernández-Hernando, Carlos (2016) Truths and controversies concerning the role of miRNAs in atherosclerosis and lipid metabolism. Curr Opin Lipidol 27:623-629
Ulrich, Victoria; Rotllan, Noemi; Araldi, Elisa et al. (2016) Chronic miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Mol Med 8:643-53
Price, Nathan L; Fernández-Hernando, Carlos (2016) miRNA regulation of white and brown adipose tissue differentiation and function. Biochim Biophys Acta 1861:2104-2110
Canfrán-Duque, Alberto; Lin, Chin-Sheng; Goedeke, Leigh et al. (2016) Micro-RNAs and High-Density Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 36:1076-84
Aryal, Binod; Rotllan, Noemi; Araldi, Elisa et al. (2016) ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression. Nat Commun 7:12313
Willeit, Peter; Skroblin, Philipp; Kiechl, Stefan et al. (2016) Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J 37:3260-3266
Rotllan, Noemi; Price, Nathan; Pati, Paramita et al. (2016) microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 246:352-60
Price, Nathan L; Holtrup, Brandon; Kwei, Stephanie L et al. (2016) SREBP-1c/MicroRNA 33b Genomic Loci Control Adipocyte Differentiation. Mol Cell Biol 36:1180-93
Pauta, Montse; Rotllan, Noemi; Fernández-Hernando, Ana et al. (2016) Akt-mediated foxo1 inhibition is required for liver regeneration. Hepatology 63:1660-74

Showing the most recent 10 out of 58 publications